Vitamin D supplementation to reduce CardioVascular risk factors
- Conditions
- Health Condition 1: null- metabolic syndrome
- Registration Number
- CTRI/2012/08/002855
- Lead Sponsor
- St Johns Research Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 140
Assessment for inclusion in the study
Individuals will be included in the study if they satisfy all of the following conditions:
i)Age 35 to 65 years
ii)Waist circumference of 90cm or more in men, and 80cm or more in women
iii)Any two of the following four factors:
•raised TG level: > 150 mg/d, or specific treatment for this lipid abnormality
•reduced HDL cholesterol: < 40 mg/dL in males and < 50 mg/dL in females, or specific treatment for this lipid abnormality
•raised blood pressure: systolic BP 130 or diastolic BP 85 mm Hg, or treatment of previously diagnosed hypertension
• fasting plasma glucose (FPG) 100 mg/dL (5.6 mmol/L)
1.Known diabetes or pre-diabetes defined as a Fasting Blood Sugar >110 mg/dl.
2.Receiving/received Vitamin D or calcium supplementation in the previous 3 months
3. History of Chronic disease-renal/ hepatic/ malignancy /gastrointestinal ( Mal absorption syndromes )
4.Patients who have received Anticonvulsants, glucocorticoids or ART medication in the past one month
5.Pregnancy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reduction of insulin resistance calculated by HOMA IR at the end of 6 monthsTimepoint: Reduction of insulin resistance calculated by HOMA IR at month 6
- Secondary Outcome Measures
Name Time Method ATimepoint: NA